Skip to main content
. Author manuscript; available in PMC: 2019 Dec 13.
Published in final edited form as: Ann Rheum Dis. 2009 Sep 3;69(5):872–875. doi: 10.1136/ard.2009.112920

Figure 2.

Figure 2

Denosumab increased bone mineral density (BMD) at the lumbar spine and total hip and reduced levels of the bone turnover markers serum type I C-telopeptide (sCTx-I) and serum procollagen 1N-terminal peptide (P1NP), regardless of concomitant treatment with bisphosphonates. Denosumab or placebo was administered on study day 1 and at 6 months; BMD levels increased steadily starting with the first dose. Suppression of bone turnover markers was evident 3 months after the first dose; levels began to return to baseline levels as the end of each 6-month dosing interval approached. Q1, first quartile; Q3, third quartile.